NCI/DCCPS R21 Program Announcements

The funding opportunity announcements (FOAs) on this site provide the option for R21 applications. R21 grants support the promotion of early and developmental stages of research efforts on novel scientific ideas that have the potential to substantially advance cancer research in all areas relevant to the mission of NCI. Applications submitted under this mechanism should break new ground or extend previous discoveries toward new directions or applications.

  • The combined budget for direct costs for the 2-year project period may not exceed $275,000
  • No more than $200,000 may be requested in any single year.
  • Applicants may request direct costs in $25,000 modules, up to the total direct costs limitation of $275,000 for the combined 2-year award period (unless otherwise specified in the FOA).

Behavioral Research

(Active R21 Grants in Behavioral Research)

Title Announcement End date Contact
End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R21 Clinical Trial Optional) PA-18-499 May 8, 2021 Sylvia Chou
240-276-6954
chouws@mail.nih.gov
Exploratory/Developmental Clinical Research Grants in Obesity (R21 Clinical Trial Optional) PA-18-720 May 8, 2021 Tanya Agurs-Collins
240-276-6956
collinsta@mail.nih.gov
Testing Interventions for Health-Enhancing Physical Activity (R21/R33 Clinical Trial Optional) PAR-18-307 January 9, 2021 Frank Perna
240-276-6782
pernafm@mail.nih.gov
Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 Clinical Trial Not Allowed) PAR-17-475 June 28, 2020 For cancer-related FOA questions:
Rachel Grana Mayne
240-276-5899
rachel.mayne@nih.gov

For general FOA questions:
Dionne C. Godette
Office of Disease Prevention (ODP)
301-480-1161
dionne.godette@nih.gov
U.S. Tobacco Control Policies to Reduce Health Disparities (R21 Clinical Trial Optional) PAR-18-674 June 16, 2020 Bob Vollinger
240-276-6919
Bob.Vollinger@nih.gov

Annette Kaufman
240-276-6706
kaufmana@mail.nih.gov
Nutrition and Alcohol-Related Health Outcomes (R21) PA-17-213 May 8, 2020 Rosalind Breslow
301-594-6231
rbreslow@mail.nih.gov
Tobacco Use and HIV in Low and Middle Income Countries (R21 Clinical Trial Optional) PAR-18-022 January 8, 2020 Mark Parascandola
240-276-6871
mark.parascandola@nih.gov
Perception and Cognition Research to Inform Cancer Image Interpretation (R21 Clinical Trial Optional) PAR-18-641 September 27, 2019 Todd Horowitz
240-276-6963
horowitzts@mail.nih.gov
Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R21/R33 Clinical Trial Optional) PAR-18-086 September 8, 2019 Glen Morgan
240-276-6787
gmorgan@nih.gov
Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional) PAR-18-084 September 8, 2019 Glen Morgan
240-276-6787
gmorgan@mail.nih.gov
Cancer-Related Behavioral Research through Integrating Existing Data (R21) PAR-16-255 June 15, 2019 Richard Moser
240-276-6915
moserr@mail.nih.gov
Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R21 Clinical Trial Optional) PAR-18-250 June 14, 2019 Yvonne Prutzman
240-276-6975
huntym@mail.nih.gov
Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21 Clinical Trial Optional) PAR-18-639 June 14, 2019 Kelly Blake
240-281-5934
kelly.blake@nih.gov
Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional) PAR-18-018 May 8, 2019 Tanya Agurs-Collins
240-276-6956
collinsta@mail.nih.gov
Population Health Interventions: Integrating Individual and Group Level Evidence (R21 Clinical Trial Optional) PA-18-407 May 8, 2019 David Berrigan
240-276-6752
berrigand@mail.nih.gov
Population Health Interventions: Integrating Individual and Group Level Evidence (R21 Clinical Trials Not Allowed) PA-18-406 May 8, 2019 David Berrigan
240-276-6752
berrigand@mail.nih.gov
Population Health Interventions: Integrating Individual and Group Level Evidence (R21 Clinical Trial Not Allowed) PA-18-406 May 8, 2019 Michael Spittel
301-451-4286
spittelm@mail.nih.gov
Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 Clinical Trial Optional) PAR-18-606 April 12, 2019 Jerry Suls
240-276-6811
jerry.suls@nih.gov
Predicting Behavioral Responses to Population-Level Cancer Control Strategies (R21 Clinical Trial Optional) PAR-18-024 April 12, 2019 Rebecca Ferrar
301-852-1167
rebecca.ferrer@nih.gov
Tobacco Regulatory Science (R21 Clinical Trial Optional) RFA-OD-18-003 February 14, 2019 Rachel Grana Mayne
240-276-5899
rachel.mayne@nih.gov
Education and Health: New Frontiers (R21 Clinical Trial Optional) PAR-18-362 January 8, 2019 Todd Horowitz
240-276-6963
todd.horowitz@nih.gov
Improving Smoking Cessation Interventions among People Living with HIV (R21 Clinical Trial Optional) RFA-CA-18-028 January 9, 2019 Annette Kaufman
240-276-6706
kaufmana@mail.nih.gov
Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) PAR-18-064 November 9, 2018 Kelly Blake
240-281-5934
kelly.blake@nih.gov

Cancer Survivorship

(Active R21 Grants in Survivorship Research)

Title Announcement End date Contact
Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional) PAR-18-892 September 8, 2021 Frank Perna
240-276-6782
pernafm@mail.nih.gov
Examination of Survivorship Care Planning Efficacy and Impact (R21 Clinical Trial Optional) PA-18-012 January 8, 2019 Stephen Taplin
240-276-6947
taplins@mail.nih.gov

Epidemiology and Genomics Research

(Active R21 Grants in Epidemiology and Genomics Research)

Title Announcement End date Contact
Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed) PAR-18-857 September 8, 2021 Amy Subar
240-276-6695
subara@mail.nih.gov
Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression Announcement Numbers (R21 Clinical Trial Optional) PA-18-739 May 8, 2021 Tram Lam
240-276-6967
lamt@mail.nih.gov
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) PA-18-678 May 8, 2021 Tram Lam
240-276-6967
lamt@mail.nih.gov
Early-life Factors and Cancer Development Later in Life (R21 Clinical Trial Not Allowed) PA-18-532 January 8, 2021 Somdat Mahabir
240-276-6941
Mahabir@mail.nih.gov
Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21) PA-17-446 September 8, 2020 Charlisse Caga-anan
240-276-6738
charlisse.caga-anan@nih.gov
Exploratory Grants in Cancer Epidemiology and Genomics Research (R21) PA-16-175 May 8, 2019 Mukesh, Verma
240-276-6889
vermam@mail.nih.gov
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional) PA-18-013 January 8, 2019 Nonniekaye Shelburne
240-276-6897
nshelburne@mail.nih.gov
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21) PAR-15-334 November 21, 2018 Juli Klemm
301-480-5778
klemmj@mail.nih.gov

Healthcare Delivery Research

(Active R21 Grants in Healthcare Delivery Research)

Title Announcement End date Contact
Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R21Clinical Trial Optional) PA-18-492 May 8, 2021 Gurvaneet Randhawa
240-276-6940
gurvaneet.randhawa@nih.gov
Methodology and Measurement in the Behavioral and Social Sciences (R21 Clinical Trial Optional) PAR-18-378 September 8, 2019 Sandra Mitchell
240-276-6929
mitchellsa@cc.nih.gov
Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33) PAR-16-367 September 8, 2019 Erica Breslau
240-276-6773
breslaue@mail.nih.gov
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21 Clinical Trial Optional) PAR-18-019 July 17, 2019 Sarah Kobrin
240-276-6931
kobrins@mail.nih.gov
Exploratory/Developmental Surgical Disparities Research (R21 Clinical Trial Optional) PAR-18-289 June 8, 2019 Brenda Adjei
240-276-6185
adjeiba@mail.nih.gov
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 Clinical Trial Optional) PAR-18-247 April 12, 2019 Michelle Mollica
240-276-7621
mollicama@mail.nih.gov
End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional) PA-18-155 January 8, 2019 Ashley Wilder Smith
240-276-6714
smithas@mail.nih.gov

Implementation Science

(Active R21 Grants in Implementation Science)

Title Announcement End date Contact
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional) PAR-18-017 May 8, 2019 David Chambers
240-276-5090
dchamber@mail.nih.gov